Clinical Trials Using Dendritic Cell-targeting Lentiviral Vector ID-LV305
Clinical trials are research studies that involve people. The clinical trials on this list are studying Dendritic Cell-targeting Lentiviral Vector ID-LV305. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Modified T Cells, Chemotherapy, and Aldesleukin with or without LV305 in Treating Participants with Advanced or Recurrent Sarcoma
This phase I trial studies how well autologous NY-ESO-1-specific CD8-positive T lymphocytes (modified T lymphocytes [T cells]), chemotherapy, and aldesleukin with or without dendritic cell-targeting lentiviral vector ID-LV305 (LV305) work in treating participants with sarcoma that has spread to other places in the body (advanced) or that has come back (recurrent). Modified T cells used in this study are taken from participants, are changed in a laboratory, and may "kill" some types of tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide may help the body get ready to receive the modified T cells. Interleukins, such as aldesleukin, are proteins made by white blood cells and other cells in the body and may help regulate immune response. LV305 may help stimulate the immune system. Giving modified T cells, chemotherapy, aldesleukin, and LV305 may work better in treating participants with sarcoma.
Location: M D Anderson Cancer Center, Houston, Texas